A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
Phase 2/3 single-arm trial of exagamglogene autotemcel (exa-cel), autologous CD34+ cells CRISPR-Cas9 edited at the BCL11A enhancer, in patients aged 12 to 35 with severe sickle cell disease. 29 of 30 evaluable patients had no severe vaso-occlusive crisis for 12 months or more.
| Status | Completed |
|---|---|
| Phase | Phase 2 3 |
| Primary Endpoint Result | Met |
| Enrollment | 63 |
| Start Date | 2018-11-27 |
| Primary Completion Date | 2025-07-07 |
Results Summary
In the phase 3 primary analysis (NEJM 2024; June 2023 data cut; 44 patients treated), 29 of 30 evaluable patients (97%; 95% CI 83 to 100) had no severe vaso-occlusive crisis for at least 12 consecutive months (P<0.001 against a 50% null response), and 30 of 30 had no hospitalization for such crises for 12 months. Neutrophils and platelets engrafted in all patients (median 27 and 35 days). Mean HbF was 36.9% of total hemoglobin at month 3 and at least 40% from month 6. Posted final results (46 treated): 91.3% (95% CI 79.2 to 97.6) met the 12-month crisis-free endpoint; mean annualized red-cell units transfused after month 12 was 0 (n=45). Grade 3 or 4 adverse events occurred in 42 of 44 (paper), mostly from busulfan (stomatitis 55%, febrile neutropenia 48%); serious events in 22 of 46 (posted), none judged related to exa-cel (paper). No graft failure or cancer. One patient died of SARS-CoV-2 respiratory failure 268 days after infusion.
Design Implications
Editing the erythroid-specific BCL11A enhancer, rather than the coding sequence, raised HbF to at least 40% of total hemoglobin and stopped severe crises in nearly all evaluable patients, supporting lineage-restricted knockdown of a fetal-hemoglobin repressor as a mutation-independent route for sickle cell disease and beta-thalassemia. Benefit accompanied at least 70% edited alleles in blood and about 86% in bone marrow CD34+ cells, a benchmark for editing depth. The safety burden came from myeloablative busulfan (grade 3 or 4 events in 95%, one death with busulfan-associated lung injury) and repeated plerixafor mobilization (median 2 cycles, up to 6), not from the edit; 17 of 63 enrolled patients were never dosed. Gentler conditioning or in vivo editing of stem cells would widen eligibility. Patients with crises after infusion had HbF and editing similar to responders, so non-HbF causes (infection, chronic pain, organ damage) still need adjudication.
Rationale
Exagamglogene autotemcel (exa-cel, CTX001) is autologous CD34+ hematopoietic stem and progenitor cells edited ex vivo with CRISPR-Cas9 and a single-guide RNA at the erythroid-specific enhancer of BCL11A, a transcription factor that represses fetal hemoglobin (HbF) after birth. Disrupting the enhancer lowers BCL11A only in the erythroid lineage, so red cells make HbF again. HbF does not polymerize with sickle hemoglobin, and people with sickle cell disease who inherit persistent HbF have few or no symptoms. Raising HbF and total hemoglobin was therefore expected to eliminate vaso-occlusive crises. Patients receive busulfan myeloablation before the infusion.
Limitations
Single-arm, open-label trial with no concurrent control; efficacy is judged against a 50% null response and each patient's own crisis history. The paper's primary analysis is an interim cut (30 evaluable of 44 treated), and the posted final results (46 treated) give 91.3% rather than 97%. Only 46 of 63 enrolled patients were infused. Ages 12 to 35 only; follow-up is 2 years per patient. The registry lists phase 2/3, but the official title says phase 1/2/3.
Registry record
This is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participants with severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.
| Primary Outcomes | Percentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel Infusion, Percentage of Participants Who Achieve Neutrophil Engraftment, Time to Neutrophil Engraftment for Participants Who Achieve Neutrophil Engraftment, Time to Platelet Engraftment for Participants Who Achieve Platelet Engraftment, Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Transplant-related Mortality (TRM) Within 100 Days After Exa-cel Infusion, Transplant-related Mortality Within 12 Months Post Exa-cel Infusion, All-cause Mortality |
|---|---|
| Registry Last Updated | 2026-09-16 |
| Results First Posted Date | 2026-09-16 |
| Minimum Age | 12 Years |
| Modalities | gene_editing, cell_therapy |
| Maximum Age | 35 Years |
| Intervention Names | Exa-cel, Exagamglogene autotemcel, CTX001 |
| Allocation | Not Applicable |
| Masking | None |
| Primary Purpose | Treatment |
| Has Results | Yes |
| Enrollment Type | Actual |
| Countries | United States, Belgium, Canada, France, Germany, Italy, United Kingdom |
| Intervention Types | biological |
| Study Type | Interventional |
| Intervention Model | Single Group |
| Healthy Volunteers | No |
| Condition Terms | Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies, Anemia, Sickle Cell, Hematologic Diseases |
| Completion Date | 2025-07-07 |
| Lead Sponsor Class | Industry |
| Eligibility Sex | All |
Official Title
A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease
Eligibility Criteria
Key Inclusion Criteria:
- Diagnosis of severe sickle cell disease as defined by:
- Documented severe sickle cell disease genotype
- History of at least two severe vaso-occlusive crisis events per year for the previous two years prior to enrollment
- Eligible for autologous stem cell transplant as per investigators judgment
Key Exclusion Criteria:
- An available 10/10 human leukocyte antigen (HLA)-matched related donor
- Prior hematopoietic stem cell transplant (HSCT)
- Clinically significant and active bacterial, viral, fungal, or parasitic infection
Other protocol defined inclusion/exclusion criteria may apply.
Identifiers & revision
clinicaltrials NCT03745287ctis 2024-516067-83-00
